Inogen (INGN) Q1 2025: B2B Unit Volumes Up 27%, Offsetting DTC Weakness
Inogen’s first quarter marked a decisive shift as business-to-business (B2B) channels delivered robust 27% unit growth, balancing out persistent direct-to-consumer (DTC) softness. Operational discipline and margin stability enabled positive adjusted EBITDA for the first time in years. Investors should watch for second-half acceleration as DTC comps normalize and the UL Medical partnership expands geographic reach.
Summary
- B2B Channel Momentum: Strong double-digit unit growth in both domestic and international B2B channels drove overall top-line gains.
- Operational Efficiency Gains: Cost controls and margin discipline returned the business to adjusted EBITDA profitability.
- Second-Half Setup: DTC headwinds are expected to abate, positioning Inogen for improved growth and channel balance in H2.
Performance Analysis
Inogen’s Q1 2025 results highlight a business in transition, with B2B channels now the primary growth engine. Total revenue rose 5.5% year-over-year to $82.3 million, as domestic B2B revenue surged nearly 30% and international B2B climbed 23%. This growth was powered by higher demand from both new and existing customers, and management cited a continued shift from oxygen tanks to portable oxygen concentrators (POCs, portable oxygen devices), which is expanding the overall addressable market.
Offsetting this B2B strength, the DTC channel contracted 27%, reflecting a leaner, more efficient sales team after last year’s restructuring. Rental revenue also declined 7.5% due to a payer mix shift toward lower-reimbursing private payers, though sequential rental revenue stabilized for the first time in several quarters—a potential sign of bottoming. Gross margin held steady at 44.2%, with lower warranty expenses offsetting less favorable channel mix. Operating expense fell 13% year-over-year, supporting a return to positive adjusted EBITDA, a key inflection not seen since 2021.
- B2B Volume Surge: Domestic B2B revenue jumped to $21.5 million, with international B2B at $32 million, together now forming over 65% of total sales.
- DTC and Rental Drag: DTC and rental revenues continued to shrink, but management expects easier comps and improved efficiency ahead.
- Margin Stabilization: Gross margin improvement was modest but notable given the adverse revenue mix and persistent pricing pressure in rental.
Inogen’s cash position remains solid at $122.5 million with no debt, bolstered by a $27 million strategic investment from UL Medical. This provides ample liquidity for innovation and international expansion as the company navigates channel and market transitions.
Executive Commentary
"Our growth was driven by the continued strength of our business-to-business channels. This was offset by expected pressure in our DTC channel, where we have optimized the size of our sales team. We expect more favorable year-over-year comparisons in the back half of 2025 as we lap one year with our newer, more efficiently sized team in place."
Kevin Smith, President and CEO
"We still expect to approach adjusted EBITDA break-even for the full year 2025 as we continue to invest in innovation, the introduction of SEMIACs, and our UL rollout. We have made significant progress where we will carefully manage our expense profile and drive manufacturing and operational efficiencies going forward."
Mike Bork, CFO
Strategic Positioning
1. B2B Channel Expansion
Inogen is doubling down on B2B distribution, both domestically and internationally, as the core engine of growth. The company is capturing share from legacy oxygen tank suppliers as the market shifts toward portable oxygen concentrators, a trend management expects to continue. Recent wins with large national customers and strong unit growth evidence this channel’s momentum.
2. Direct-to-Consumer Realignment
The DTC channel has been deliberately downsized to a more profitable, efficient footprint. Management’s patient-first initiative, now 75% rolled out, is driving higher unit sales and revenue per rep, as well as lower return rates. The company expects DTC comps to normalize by Q3, setting the stage for improved year-over-year growth in the second half.
3. International and Product Portfolio Diversification
The UL Medical partnership is a strategic lever for global expansion and product breadth. Inogen will distribute its portable concentrators under its brand in China and add UL’s stationary concentrators to its US offering, broadening its portfolio. Regulatory hurdles are being addressed, with a limited US launch targeted for 2025 and a full rollout in 2026. The $27 million equity investment from UL also strengthens the balance sheet for further innovation.
4. Margin and Cost Discipline
Operational efficiency remains a top priority, with OpEx down 13% year-over-year and gross margin stable despite channel headwinds. Management cautions that Q1 OpEx is not a run-rate for the rest of the year, as some expenses will shift to later quarters, but overall cost control is expected to persist.
5. Innovation Pipeline and Digital Health
Progress continues on SEMIACs (next-gen oxygen therapy) and digital health solutions, with reimbursement and commercial pilots underway. The company is enhancing remote monitoring capabilities to drive value for patients and partners, aiming to differentiate its offering and reduce service costs over time.
Key Considerations
Strategic focus on B2B and disciplined cost management defined Q1, while innovation and channel normalization set up the second half. Investors should closely monitor:
Key Considerations:
- B2B Channel Sustainability: Sustained double-digit unit growth hinges on continued market conversion from tanks to POCs and retention of new large accounts.
- DTC Channel Inflection: The ability to deliver profitable growth as DTC comps normalize will be a key test of the revamped sales model.
- Rental Revenue Mix Shift: Private pay penetration pressures rental margins, but recent sequential stabilization could mark a turning point.
- UL Medical Execution: Timely regulatory approvals and successful product launches in both the US and China are critical for international expansion.
- Innovation Commercialization: SEMIACs and digital health initiatives must translate from pilot to scalable revenue streams to justify ongoing investment.
Risks
Persistent DTC and rental headwinds, along with payer mix pressure, could limit margin expansion if B2B growth slows or channel mix worsens. Tariff dynamics remain fluid, and while current exemptions protect gross margin, any policy changes could introduce cost volatility. Execution risk around the UL Medical partnership and regulatory delays could also impact the international growth thesis.
Forward Outlook
For Q2 2025, Inogen guided to:
- Revenue of $89 million to $91 million, representing flat to 3% growth year-over-year.
For full-year 2025, management maintained guidance:
- Revenue of $352 million to $355 million, or 5% to 6% growth.
- Approaching adjusted EBITDA breakeven for the year.
Management emphasized:
- Second-half growth rates should accelerate as DTC channel comps normalize.
- Gross margin guidance unchanged, with no current tariff-related headwinds expected.
Takeaways
Inogen’s Q1 signals a successful pivot to B2B-driven growth and cost discipline, though sustained execution is required as DTC and rental channels stabilize and new partnerships scale.
- B2B Outperformance: Channel shift to B2B is driving top-line growth and partially insulating the business from DTC volatility.
- Margin and Cost Focus: OpEx reduction and gross margin resilience support a return to profitability, but further gains depend on mix and scale.
- Watch for H2 Channel Rebound: The back half of 2025 will reveal whether DTC and rental can contribute to sustainable multi-channel growth as comps normalize.
Conclusion
Inogen’s first quarter confirms the strategic pivot toward B2B and operational rigor, with early signs of channel stabilization and innovation progress. The second half will test whether these improvements can deliver sustained growth and profitability as the channel mix rebalances and new markets come online.
Industry Read-Through
The portable oxygen market is clearly shifting from legacy tank systems to portable concentrators, benefiting vendors positioned for B2B scale and international reach. Inogen’s execution highlights the importance of channel diversification, cost discipline, and digital health integration for durable growth. Competitors relying on DTC or rental-heavy models may face continued pressure, while those with strong B2B and global strategies are best positioned to capture expanding demand and payer-driven mix shifts. The resilience of gross margins despite mix headwinds suggests that operational efficiency and innovation are increasingly critical for all players in the respiratory care space.